Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis

Neuropsychopharmacology

Volumn 36, Issue 9, 2011, Pages 1781-1791

  Fuente Sandoval, Camilo De La ^a   León Ortiz, Pablo ^a   Favila, Rafael ^b   Stephano, Sylvana ^a   Mamo, David ^c   Ramírez Bermdez, Jess ^a   Graff Guerrero, Ariel ^c  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b GE HEALTHCARE   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

1H MRS; associative striatum; dopamine; glutamate; prodromal; schizophrenia

Indexed keywords

GLUTAMIC ACID; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CAUDATE NUCLEUS; CEREBELLUM CORTEX; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GRAY MATTER; HUMAN; MALE; MENTAL PATIENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGE OF ONSET; CAUDATE NUCLEUS; DISEASE PROGRESSION; FEMALE; GLUTAMIC ACID; HUMANS; MALE; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; UP-REGULATION; YOUNG ADULT;

EID: 79960306528     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.65     Document Type: Article

References (102)

1. Aalto S, Hirvonen J, Scheinin H, Nagren K, Vilkman H, Hietala J et al (2002). Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology 164: 401.
2. Aalto S, Ihalainen J, Hirvonen J, Kajander J, Scheinin H, Tanila H et al (2005). Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharma-cology (Berl) 182: 375-383. (Pubitemid 41464649)
3. Abbott C, Bustillo J (2006). What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr Opin Psychiatry 19: 135-139. (Pubitemid 44406123)
4. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155: 761-767. (Pubitemid 28252654)
5. APA (2000). Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR 4th edn American Psychiatric Association: Wa-shington, DC, USA.
6. Ariyannur PS, Madhavarao CN, Namboodiri AM (2008). N-acetylaspartate synthesis in the brain: mitochondria vs micro-somes. Brain Res 1227: 34-41.
7. Auer DP, Wilke M, Grabner A, Heidenreich JO, Bronisch T, Wetter TC (2001). Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr Res 52: 87-99. (Pubitemid 32947051)
8. Barker PB (2001). N-acetyl aspartate-a neuronal marker? Ann Neurol 49: 423-424.
9. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L et al (1997). Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectro-scopy. Arch Gen Psychiatry 54: 959-965. (Pubitemid 28022747)
10. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB (1996). Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 7: 1397-1400. (Pubitemid 26281000)
11. Borgwardt SJ, Riecher-Rossler A, Dazzan P, Chitnis X, Aston J, Drewe M et al (2007). Regional gray matter volume abnormal-ities in the at risk mental state. Biol Psychiatry 61: 1148-1156. (Pubitemid 46669460)
12. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L et al (1998). Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29: 142-147. (Pubitemid 28221792)
13. Brodal P (2004). The central nervous system: structure and function, 3rd edn Oxford University Press: Oxford, New York.
14. Bustillo JR, Rowland LM, Jung R, Brooks WM, Qualls C, Hammond R et al (2008). Proton magnetic resonance spectro-scopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 33: 2456-2466.
15. Bustillo JR, Rowland LM, Lauriello J, Petropoulos H, Hammond R, Hart B et al (2002). High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia. Am J Psychiatry 159: 130-133. (Pubitemid 41070738)
16. Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C et al (2010). 1H-MRS at 4 tesla in minimally treated early schizo-phrenia. Mol Psychiatry 15: 629-636.
17. Cadenhead KS (2002). Vulnerability markers in the schizophrenia spectrum: implications for phenomenology, genetics, and the identification of the schizophrenia prodrome. Psychiatr Clin North Am 25: 837-853. (Pubitemid 35351209)
18. Cadenhead KS, Addington J, Cannon T, Cornblatt B, Mc Glashan T, Perkins D et al (2010). Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Early Interv Psychiatry 4: 220-226.
19. Camps M, Cortes R, Gueye B, Probst A, Palacios JM (1989). Dopamine receptors in human brain: Autoradiographic dis-tribution of D2 sites. Neuroscience 28: 275.
20. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E et al (2008). Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 65: 28-37.
21. Carlsson M, Carlsson A (1990). Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implica-tions for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272-276. (Pubitemid 20193457)
22. Cepeda C, Levine MS (1998). Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci 20: 1-18. (Pubitemid 28132701)
23. Chua SE, Cheung C, Cheung V, Tsang JT, Chen EY, Wong JC et al (2007). Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia. Schizophr Res 89: 12-21. (Pubitemid 44895585)
24. Clementi V, Tonon C, Lodi R, Malucelli E, Barbiroli B, Iotti S (2005). Assessment of glutamate and glutamine contribution to in vivo N-acetylaspartate quantification in human brain by (1)H-magnetic resonance spectroscopy. Magn Reson Med 54: 1333-1339. (Pubitemid 41740762)
25. David HN, Ansseau M, Abraini JH (2005). Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of ''intact'' animals. Brain Res Brain Res Rev 50: 336-360. (Pubitemid 41654400)
26. De Keyser J, Claeys A, De Backer JP, Ebinger G, Roels F, Vauquelin G (1988). Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neurosci Lett 91: 142-147.
27. de la Fuente-Sandoval C, Favila R, Alvarado P, Leon-Ortiz P, Diaz-Galvis L, Amezcua C et al (2009). Glutamate increase in the associative striatum in schizophrenia: a longitudinal magnetic resonance spectroscopy preliminary study. Gac Med Mex 145: 109-113.
28. Di Costanzo A, Trojsi F, Tosetti M, Giannatempo GM, Nemore F, Piccirillo M et al (2003). High-field proton MRS of human brain. Eur JRadiol48: 146-153. (Pubitemid 37378232)
29. Di Costanzo A, Trojsi F, Tosetti M, Schirmer T, Lechner SM, Popolizio T et al (2007). Proton MR spectroscopy of the brain at 3 T: an update. Eur Radiol 17: 1651-1662. (Pubitemid 46909653)
30. Dum RP, Strick PL (2003). An unfolded map of the cerebellar dentate nucleus and its projections to the cerebral cortex. J Neurophysiol 89: 634-639. (Pubitemid 36134050)
31. Edden RA, Pomper MG, Barker PB (2007). In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. Magn Reson Med 57: 977-982. (Pubitemid 46911282)
32. Eluri R, Paul C, Roemer R, Boyko O (1998). Single-voxel proton magnetic resonance spectroscopy of the pons and cerebellum in patients with schizophrenia: a preliminary study. Psychiatry Res 84: 17-26. (Pubitemid 28546880)
33. Farde L, Wiesel FA, Halldin C, Sedvall G (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71-76. (Pubitemid 18018572)
34. First MB, Spitzer RL, Williams JB, Gibbon M (1997). Structured Clinical Interview for DSM-IV Disorders (SCID). American Psychiatric Association: Washington, DC
35. Friston KJ, Ashburner J, Frith CD, Poline JB, Heather JD, Frackowiak RSJ (1995). Spatial registration and normalization of images. Hum Brain Mapp 3: 165-189. (Pubitemid 3036540)
36. Grace AA (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1-24.
37. Grace AA (1993). Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia. J Neural Transm 91: 111-134. (Pubitemid 23131300)
38. Grace AA (2000). Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev 31: 330-341. (Pubitemid 30136188)
39. Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P et al (2008). Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp 29: 400-410. (Pubitemid 351522134)
40. Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J et al (1999). Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 35: 41-50. (Pubitemid 29023553)
41. Horrobin DF, Glen AI, Vaddadi K (1994). The membrane hypothesis of schizophrenia. Schizophr Res 13: 195-207. (Pubitemid 24302649)
42. Howes OD, Kapur S (2009a). The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 35: 549-562.
43. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P et al (2009b). Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66: 13-20.
44. Hurd R, Sailasuta N, Srinivasan R, Vigneron DB, Pelletier D, Nelson SJ (2004). Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn Reson Med 51: 435-440. (Pubitemid 38298653)
45. Jahshan C, Heaton RK, Golshan S, Cadenhead KS (2010). Course of neurocognitive deficits in the prodrome and first episode of schizophrenia. Neuropsychology 24: 109-120.
46. Javitt DC (2007). Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interac-tions. Int Rev Neurobiol 78: 69-108.
47. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
48. Jayakumar PN, Venkatasubramanian G, Gangadhar BN, Janakir-amaiah N, Keshavan MS (2005). Optimized voxel-based mor-phometry of gray matter volume in first-episode, antipsychotic-naive schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29: 587-591. (Pubitemid 40603835)
49. Kapur S (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am JPsychiatry 160: 13-23. (Pubitemid 36042420)
50. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000). Relationship between dopamine D(2) occupancy, clinical re-sponse, and side effects: a double-blind PET study of first-episode schizophrenia. Am JPsychiatry 157: 514-520. (Pubitemid 30191189)
51. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M et al (2010). Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67: 231-239.
52. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL et al (2000). Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48: 627-640.
53. Kegeles LS, Martinez D, Kochan LD, Hwang DR, Huang Y, Mawlawi O et al (2002). NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans. Synapse 43: 19.
54. Kelly RM, Strick PL (2003). Cerebellar loops with motor cortex and prefrontal cortex of a nonhuman primate. J Neurosci 23: 8432-8444. (Pubitemid 37129661)
55. Keshavan MS, Dick RM, Diwadkar VA, Montrose DM, Prasad KM, Stanley JA (2009). Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectro-scopy study. Schizophr Res 115: 88-93.
56. Kulagina NV, Zigmond MJ, Michael AC (2001). Glutamate regulates the spontaneous and evoked release of dopamine in the rat striatum. Neuroscience 102: 121-128. (Pubitemid 32171858)
57. Laruelle M, Abi-Dargham A, Van Dyck CH, Gil R, D?Souza CD, Erdos J et al (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235.
58. Lehericy S, Ducros M, Krainik A, Francois C, Van de Moortele PF, Ugurbil K et al (2004). 3-D diffusion tensor axonal tracking shows distinct SMA and pre-SMA projections to the human striatum. Cereb Cortex 14: 1302-1309. (Pubitemid 39507281)
59. Levine MS, Cepeda C (1998). Dopamine modulation ofresponses mediated by excitatory amino acids in the neostriatum. Adv Pharmacol 42: 724-729.
60. Lieberman JA, Stroup TS, Mc Evoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223. (Pubitemid 41345943)
61. Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, Huttunen MO et al (2010). Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry 15: 308-318.
62. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S (2007). Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am JPsychiatry 164: 1411-1417. (Pubitemid 47461142)
63. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR et al (2001). Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21: 1034-1057. (Pubitemid 32823740)
64. Mayer D, Spielman DM (2005). Detection of glutamate in the human brain at 3 T using optimized constant time point resolved spectroscopy. Magn Reson Med 54: 439-442. (Pubitemid 41033562)
65. Middleton FA, Strick PL (2001). Cerebellar projections to the prefrontal cortex of the primate. J Neurosci 21: 700-712. (Pubitemid 32107458)
66. Miller TJ, Mc Glashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J et al (2003). Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 29: 703-715. (Pubitemid 38181951)
67. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927. (Pubitemid 27155025)
68. O'Neill J, Levitt J, Caplan R, Asarnow R, Mc Cracken JT, Toga AW et al (2004). 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia. Neuroimage 21: 1781-1789. (Pubitemid 38446598)
69. Ohrmann P, Siegmund A, Suslow T, Spitzberg K, Kersting A, Arolt V et al (2005). Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 73: 153-157. (Pubitemid 40093876)
70. Olbrich HM, Valerius G, Rusch N, Buchert M, Thiel T, Hennig J et al (2008). Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectro-scopy study. World J Biol Psychiatry 9: 59-63. (Pubitemid 351250521)
71. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52: 998-1007.
72. Olney JW, Labruyere J, Price MT (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360-1362. (Pubitemid 19170513)
73. Pantelis C, Velakoulis D, Mc Gorry PD, Wood SJ, Suckling J, Phillips LJ et al (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361: 281-288. (Pubitemid 36126187)
74. Provencher SW (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30: 672-679. (Pubitemid 23360802)
75. Purdon SE, Valiakalayil A, Hanstock CC, Seres P, Tibbo P (2008). Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia. Schizophr Res 99: 218-224.
76. Rajji TK, Ismail Z, Mulsant BH (2009). Age at onset and cognition in schizophrenia: meta-analysis. Br JPsychiatry 195: 286-293.
77. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E et al (2005). Effects ofketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 162: 394-396. (Pubitemid 40216226)
78. Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P et al (2010). Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 67: 241-251.
79. Saraceno B (2002). The WHO World Health Report 2001 on mental health. Epidemiol Psichiatr Soc 11: 83-87.
80. Sato M, Numachi Y, Hamamura T (1992). Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 18: 115-122.
81. Schmahmann JD, Pandya DN (1995). Prefrontal cortex projections to the basilar pons in rhesus monkey: implications for the cerebellar contribution to higher function. Neurosci Lett 199: 175-178.
82. Seeman P, Kapur S (2000). Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci USA 97: 7673-7675.
83. Segovia G, Del Arco A, Mora F (1997). Endogenous glutamate increases extracellular concentrations of dopamine, GABA, and taurine through NMDA and AMPA/kainate receptors in striatum of the freely moving rat: a microdialysis study. J Neurochem 69: 1476-1483. (Pubitemid 27406948)
84. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S (2001). Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 24: 330-334. (Pubitemid 32455433)
85. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA et al (1998). Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18: 18-25. (Pubitemid 28116370)
86. Stanley JA, Kipp H, Greisenegger E, Mac Master FP, Panchalingam K, Pettegrew JW et al (2006). Regionally specific alterations in membrane phospholipids in children with ADHD: An in vivo 31P spectroscopy study. Psychiatry Res 148: 217-221. (Pubitemid 44750591)
87. Steen RG, Hamer RM, Lieberman JA (2005). Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 30: 1949-1962. (Pubitemid 43093497)
88. Stone JM, Day F, Tsagaraki H, Valli I, Mc Lean MA, Lythgoe DJ et al (2009). Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry 66: 533-539.
89. Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P, Lythgoe DJ et al (2010). Altered relationship between hippocampal gluta-mate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry 68: 599-602.
90. Théberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N et al (2003). Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects mea-sured with 4.0-T proton MRS. Am JPsychiatry 160: 2231-2233. (Pubitemid 39619619)
91. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am JPsychiatry 159: 1944-1946. (Pubitemid 35283267)
92. Théberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK et al (2007). Longitudinal grey-matter and glutama-tergic losses in first-episode schizophrenia. Br J Psychiatry 191: 325-334. (Pubitemid 47555981)
93. Tibbo P, Hanstock CC, Asghar S, Silverstone P, Allen PS (2000). Proton magnetic resonance spectroscopy (1H-MRS) of the cerebellum in men with schizophrenia. J Psychiatry Neurosci 25: 509-512. (Pubitemid 33702244)
94. Tibbo P, Hanstock C, Valiakalayil A, Allen P (2004). 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 161: 1116-1118. (Pubitemid 38736001)
95. van Elst LT, Valerius G, Buchert M, Thiel T, Rusch N, Bubl E et al (2005). Increased prefrontal and hippocampal glutamate con-centration in schizophrenia: evidence from a magnetic reso-nance spectroscopy study. Biol Psychiatry 58: 724-730. (Pubitemid 41547240)
96. Villalta-Gil V, Vilaplana M, Ochoa S, Haro JM, Dolz M, Usall J et al (2006). Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients? Schizophr Res 87: 246-253. (Pubitemid 44467857)
97. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL (2000). Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34: 35-43. (Pubitemid 30006939)
98. West AR, Floresco SB, Charara A, Rosenkranz JA, Grace AA (2003). Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann N Y Acad Sci 1003: 53-74. (Pubitemid 38083045)
99. Wood SJ, Kennedy D, Phillips LJ, Seal ML, Yucel M, Nelson B et al (2010). Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Neuroimage 52: 62-68.
100. Yung AR, Mc Gorry PD (1996). The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 22: 353-370. (Pubitemid 26174579)
101. Yung AR, Phillips LJ, Yuen HP, Francey SM, Mc Farlane CA, Hallgren M et al (2003). Psychosis prediction: 12-month follow up of a high-risk (''prodromal'') group. Schizophr Res 60: 21-32. (Pubitemid 36015785)
102. Zhang Y, Marenco S, Shen J (2007). Correction of frequency and phase variations induced by eddy currents in localized spectro-scopy with multiple echo times. Magn Reson Med 58: 174-178. (Pubitemid 47229930)